Nasdaq notified BioXcel Therapeutics Inc. on August 31, 2026, that its common stock will be delisted. This action follows the company’s voluntary Chapter 11 bankruptcy filing on August 27, 2026. Nasdaq will suspend trading of BTAI shares at the market open on September 8, 2026.
BioXcel confirmed it will not appeal the delisting decision. The company expects its shares to move to the OTC Pink Limited Market following the suspension.
The bankruptcy proceedings include an asset sale agreement with Teva Pharmaceuticals. Teva will serve as the stalking horse bidder for the company's assets.